Related references
Note: Only part of the references are listed.Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors
Li Zhu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype
Kevin M. Levine et al.
NPJ BREAST CANCER (2019)
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
Katherine A. Hoadley et al.
CELL (2018)
Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer
Marni B. Siegel et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Immunological differences between primary and metastatic breast cancer
B. Szekely et al.
ANNALS OF ONCOLOGY (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration
James M. McFarland et al.
NATURE COMMUNICATIONS (2018)
Optimizing (neo) adjuvant treatment of HER2-positive breast cancer
Reva K. Basho et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
COSMIC: somatic cancer genetics at high-resolution
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases
Nolan Priedigkeit et al.
JAMA ONCOLOGY (2017)
How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment
Diana P. Saraiva et al.
ESMO OPEN (2017)
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Juan M. Cejalvo et al.
CANCER RESEARCH (2017)
Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients
Rin Ogiya et al.
CANCER SCIENCE (2016)
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation
Thomas Welte et al.
NATURE CELL BIOLOGY (2016)
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Itay Tirosh et al.
SCIENCE (2016)
S100A8/A9 is associated with estrogen receptor loss in breast cancer
Yi Bao et al.
ONCOLOGY LETTERS (2016)
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis
Anna-Maria Georgoudaki et al.
CELL REPORTS (2016)
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
Celine Lefebvre et al.
PLOS MEDICINE (2016)
Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases
Bettina Sobottka et al.
ONCOIMMUNOLOGY (2016)
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib
Aleix Prat et al.
JAMA ONCOLOGY (2016)
An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells
Olga Novikov et al.
MOLECULAR PHARMACOLOGY (2016)
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
Brett Wallden et al.
BMC MEDICAL GENOMICS (2015)
S100A9 expressed in ER-PgR- breast cancers induces inflammatory cytokines and is associated with an impaired overall survival
Caroline Bergenfelz et al.
BRITISH JOURNAL OF CANCER (2015)
A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer
Nicholas C. D'Amato et al.
CANCER RESEARCH (2015)
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Giovanni Ciriello et al.
CELL (2015)
Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2(+) breast cancers
Ruth Rodriguez-Barrueco et al.
GENES & DEVELOPMENT (2015)
Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms
Tamas Roszer
MEDIATORS OF INFLAMMATION (2015)
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
Margit Hagel et al.
CANCER DISCOVERY (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study
Eduardo Martinez de Duenas et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Aleix Prat et al.
CLINICAL CANCER RESEARCH (2014)
An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer
Michael L. Gatza et al.
NATURE GENETICS (2014)
Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
Tarrik M. Zaid et al.
CLINICAL CANCER RESEARCH (2013)
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
Shunqiang Li et al.
CELL REPORTS (2013)
Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse
J. Chuck Harrell et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan et al.
CELL (2012)
Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models
Patrick J. Roberts et al.
CLINICAL CANCER RESEARCH (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
Dorothy M. French et al.
PLOS ONE (2012)
Molecular signatures database (MSigDB) 3.0
Arthur Liberzon et al.
BIOINFORMATICS (2011)
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures
Cheng Fan et al.
BMC MEDICAL GENOMICS (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
Craig H. Mermel et al.
GENOME BIOLOGY (2011)
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study
Harri Sihto et al.
BREAST CANCER RESEARCH (2011)
Metastatic Behavior of Breast Cancer Subtypes
Hagen Kennecke et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells
A. Roidl et al.
ONCOGENE (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat et al.
BREAST CANCER RESEARCH (2010)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention
Han Kiat Ho et al.
JOURNAL OF HEPATOLOGY (2009)
INPP5E mutations cause primary cilium signaling defects, ciliary instability and ciliopathies in human and mouse
Monique Jacoby et al.
NATURE GENETICS (2009)
Mammary development meets cancer genomics
Aleix Prat et al.
NATURE MEDICINE (2009)
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
Elgene Lim et al.
NATURE MEDICINE (2009)
The FGF family: biology, pathophysiology and therapy
Andrew Beenken et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Subtypes of breast cancer show preferential site of relapse
Marcel Smid et al.
CANCER RESEARCH (2008)
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
Patrick J. Medina et al.
CLINICAL THERAPEUTICS (2008)
Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer
Danielle Meijer et al.
ENDOCRINE-RELATED CANCER (2008)
Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle
Henrik Daub et al.
MOLECULAR CELL (2008)
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells
Dorothee Duluc et al.
BLOOD (2007)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
HEF1-Dependent aurora a activation induces disassembly of the primary cilium
Elena N. Pugacheva et al.
CELL (2007)
S100A8 and S100A9 in inflammation and cancer
Christoffer Gebhardt et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers
SS Cross et al.
HISTOPATHOLOGY (2005)
The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression
JH Wang et al.
CLINICAL CANCER RESEARCH (2004)
Involvement of the FGFr4 Arg388 allele in head and neck squamous cell carcinoma
S Streit et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1α
RNH Shah et al.
ONCOGENE (2002)
Empirical Bayes methods and false discovery rates for microarrays
B Efron et al.
GENETIC EPIDEMIOLOGY (2002)
Empirical Bayes analysis of a microarray experiment
B Efron et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling
U Cavallaro et al.
NATURE CELL BIOLOGY (2001)
Binding of heparin/heparan sulfate to fibroblast growth factor receptor 4
BM Loo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Significance analysis of microarrays applied to the ionizing radiation response
VG Tusher et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
